ReviewFrontiers in toxicology2023
Innovative tools and methods for toxicity testing within PARC work package 5 on hazard assessment.
Review in Frontiers in toxicology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Comparative toxicity of plant protection products, their active substances and mixtures in zebrafish embryos and HepaRG cells.Archives of toxicology · 2026Article
- "The Dose Makes the Poison": Relevance of Paracelsus's Principle for Modern Chemical Hazard Assessment with New Approach Methodologies.Environmental science & technology · 2026Article
- Editorial: European partnership on the assessment of risks from chemicals (PARC): continued focus on new approach methodologies (NAMs) and data gap filling.Frontiers in toxicology · 2026Article
- From prioritization to implementation: updating the PARC WP5 project portfolio through the second prioritization round.Frontiers in toxicology · 2026Review
- The PrecisionTox chemical library: creation of a chemical collection to discover evolutionary conserved biomolecular signatures of toxicity.Toxicological sciences : an official journal of the Society of Toxicology · 2025Article
- Gemfibrozil's cytotoxicity and DNA protection: PPAR-α agonism overrides genotoxicity in lymphocytes.Archives of toxicology · 2025Article
- Leveraging Zebrafish Embryo Phenotypic Observations to Advance Data-Driven Analyses in Toxicology.Environmental science & technology · 2025Article
- Assessing biologic/toxicologic effects of extractables from plastic contact materials for advanced therapy manufacturing using cell painting assay and cytotoxicity screening.Scientific reports · 2024Article
- Science evolves but outdated testing and static risk management in the US delay protection to human health.Frontiers in toxicology · 2024Article
- Impact of a varied set of stimuli on a suite of immunological parameters within peripheral blood mononuclear cells: toward a non-animal approach for assessing immune modulation by materials intended for human use.Frontiers in toxicology · 2024Article
- New approach methodologies to enhance human health risk assessment of immunotoxic properties of chemicals - a PARC (Partnership for the Assessment of Risk from Chemicals) project.Frontiers in toxicology · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New approach methodologies (NAMs) have the potential to become a major component of regulatory risk assessment, however, their actual implementation is challenging. The European Partnership for the Assessment of Risks from Chemicals (PARC) was designed to address many of the challenges that exist for the development and implementation of NAMs in modern chemical risk assessment. PARC's proximity to national and European regulatory agencies is envisioned to ensure that all the research and innovation projects that are initiated within PARC agree with actual regulatory needs. One of the main aims of PARC is to develop innovative methodologies that will directly aid chemical hazard identification, risk assessment, and regulation/policy. This will facilitate the development of NAMs for use in risk assessment, as well as the transition from an endpoint-based animal testing strategy to a more mechanistic-based NAMs testing strategy, as foreseen by the Tox21 and the EU Chemical's Strategy for Sustainability. This work falls under work package 5 (WP5) of the PARC initiative. There are three different tasks within WP5, and this paper is a general overview of the five main projects in the Task 5.2 '
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.